News & Updates
Filter by Specialty:

No benefit from adding interferon beta-1a to remdesivir in COVID-19
Adding interferon beta-1a to remdesivir did not hasten time to recovery among adults hospitalized with COVID-19, according to results of the phase III ACTT*-3 trial.
No benefit from adding interferon beta-1a to remdesivir in COVID-19
16 Dec 2021
Is prior allergy a deal-breaker for COVID-19 vacc?
A large prospective, observational study has suggested that while individuals with a history of high-risk allergy may have an increased risk of allergic reactions following receipt of a messenger RNA (mRNA) COVID-19 vaccine, they are still able to receive both vaccine doses.
Is prior allergy a deal-breaker for COVID-19 vacc?
13 Dec 2021
Saliva outperforms nasopharyngeal swabs for COVID-19 detection
Compared with nasopharyngeal swabs (NPS), saliva samples provide higher diagnostic yield for detecting positivity to the coronavirus disease 2019 (COVID-19), a recent study has found.
Saliva outperforms nasopharyngeal swabs for COVID-19 detection
13 Dec 2021
Short-course, high-dose gatifloxacin gets a pass in multidrug-resistant TB with caveat
A short-term treatment regimen based on high-dose gatifloxacin appears to be effective against multidrug- or rifampicin-resistant tuberculosis (TB) but at the cost of increased severe adverse drug reactions, as shown in a study.